2 completed, 2 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Exscientia AI Limited: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2) No Interventions - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse | Completed | Exscientia AI Limited | 91 | 2024-05-13 | 2025-08-26 | |
| Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer Biological sample collection - Epithelial Ovarian Cancer | Terminated | Exscientia AI Limited | 13 | 2023-04-14 | 2024-09-26 | |
| Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours EXS21546 - Advanced Solid Tumours | Phase 1 / Phase 2 | Terminated | Exscientia AI Limited | 6 | 2023-04-11 | 2023-11-08 |
| 3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546 EXS21546 Powder for Oral Suspension, EXS21546 Granule in Capsule, Midazolam - Oncology | Phase 1 | Completed | Exscientia AI Limited | 64 | 2020-12-08 | 2022-05-16 |
Carcinoma, Ovarian Epithelial (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Recurrence (1)
Capsules (1) · Midazolam (1) · Suspensions (1)
Austria (2) · Germany (2) · Belgium (1) · Finland (1) · France (1) · United Kingdom (1)
Nikolaus Krall, Dr. (2) · Antoine Italiano, MD (1) · Phillip Evans (1)